Siemens to Market Molecular Imaging System for Researchers
By Biotechdaily staff writers
Posted on 15 Aug 2003
A molecular imaging system designed for use in the study of disease processes and drug development with features suited for in vivo imaging of mice or other small animals is to be exclusively marketed by Siemens Medical Solutions (Erlangen, Germany) in the United States, according to an agreement announced by Siemens and Gamma Medica, Inc. (Northridge, CA, USA). Posted on 15 Aug 2003
Called X-SPECT, the system combines the functional nuclear imaging technique of single photon emission computed tomography (SPECT) with the anatomical imaging provided by computed tomography (CT). The gantry is similar to popular clinical systems but on a smaller scale more suited for small animals in a laboratory setting. Gamma Medica develops and manufactures nuclear medical imaging cameras and equipment. X-SPECT is a second-generation system of the company's MicroSPECT system.
"When we started selling MicroSPECT systems, we were essentially creating a new market. Today, the product is aiding scientific research by furthering the understanding of disease, assisting in the search for treatments, and speeding up the process of getting drugs to the market,” noted Bradley E. Patt, Ph.D., president and CEO of Gamma Medica.
Related Links:
Siemens Medical Systems
Gamma Medica
Gold Member
Collection and Transport System
PurSafe Plus®
Clinical Chemistry System
P780
Urine Chemistry Control
Dropper Urine Chemistry Control
